Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Guidance tracker
What LAURUSLABS guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 03 Nov 2026 | Laurus Labs filed the transcript of its Q2 FY27 results conference call hosted on October 29, 2026. Management reported Q2 total income from operations of INR2,206 crores (highest ever for a quarter), EBITDA of INR762 crores (34.5% margin) and profit after tax of INR441 crores; H1 total income was INR4,233 crores... NSE copy | No results filed since | ||
| 18 Sep 2026 | Laurus Labs filed its September 2026 investor presentation with BSE and NSE, also uploaded to the company website. FY26 revenue was ₹6,813 Cr (up 23% CAGR over FY20-26); FY26 EBITDA was ₹1,826 Cr (up 64%) with EBITDA margin of 26.8%; net debt/EBITDA was 1.3x. Management said it is guiding for EBITDA margin above... NSE copy | +126.4 % | +33.4 % | +7.2 % |
| 30 Jul 2026 | Laurus Labs filed the transcript of its Q1 FY27 earnings conference call hosted on July 24, 2026. Management said revenue from operations was INR2,026 crores, up 29% year-on-year, with gross margin at 62.7% and EBITDA of INR644 crores (31.8% margin); profit after tax was about INR368 crores. CDMO small molecule... NSE copy | +126.4 % | +33.4 % | +7.2 % |
| 05 May 2026 | Laurus Labs filed the transcript of its Q4 FY26 results conference call, hosted on April 30, 2026. Management said FY26 revenue was INR6,813 crores (up 23%), with EBITDA of INR1,826 crores at a 26.8% margin and profit after tax of INR889 crores (up 148%). Management said Q4 revenue was INR1,812 crores (up 5%) and... NSE copy | +125.5 % | +29.1 % | +7.0 % |
| 28 Jan 2026 | Laurus Labs filed the transcript of its Q3 FY26 results conference call, hosted on January 23, 2026. Management reported Q3 total income from operations of Rs. 1,778 crore (26% growth), gross margin of 60.9% and EBITDA margin of 27%; 9-month income of Rs. 5,001 crore (30% growth) and 9-month PAT of Rs. 610 crore.... NSE copy | - | - | +5.9 % |
| 23 Jan 2026 | Laurus Labs filed the investor/analyst presentation for its unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, for a call on January 23, 2026 at 5:00 PM IST. 9M FY2026 revenue was ₹5,001 Cr, up 30%, led by the CDMO division with a robust Generics division. 9M... NSE copy | - | - | +5.9 % |
| 28 Oct 2025 | Laurus Labs filed the transcript of its Q2 FY26 results conference call, hosted on October 23, 2025. Management reported Q2 revenue of INR1,653 crores (up 35%), H1 total income of INR3,223 crores (up 33%), Q2 EBITDA of INR429 crores at a 26% margin, and Q2 profit after tax of INR195 crores. CDMO Q2 sales were... NSE copy | +172.7 % | +25.7 % | -1.6 % |
| 23 Oct 2025 | Laurus Labs filed the investor/analyst presentation on its standalone and consolidated results for the quarter and half-year ended September 30, 2025 (Q2 & H1 FY2026), for a call held October 23, 2025 at 5:00 p.m. IST. H1 revenue was ₹3,223 Cr, up 33%, per the presentation; EBITDA was ₹818 Cr at a 25.4% margin, up... NSE copy | +172.7 % | +25.7 % | -1.6 % |
| 29 Jul 2025 | Laurus Labs filed the transcript of its Q1 FY26 earnings conference call, hosted on July 25, 2025. Management said Q1 revenue was INR1,570 crores (up 31% year-on-year), with CDMO sales of INR493 crores and Generics sales of INR1,048 crores (up 12%); Laurus Bio sales were INR29 crores, flat year-on-year. CFO V.V.... NSE copy | +882.7 % | +35.1 % | -0.9 % |
| 28 Apr 2025 | Laurus Labs filed the transcript of its Q4 FY25 results conference call hosted on April 24, 2025. Management reported FY25 revenue of INR5,554 crores (up 10%), with Q4 revenue of INR1,720 crores (up 19% year on year), gross margin of 55.4% for the full year, and full-year EBITDA margin of 20.1%. Full-year profit... NSE copy | +1203.1 % | +31.4 % | +6.1 % |
| 24 Apr 2025 | Laurus Labs filed an investor/analyst presentation on its standalone and consolidated financial results for the quarter and year ended March 31, 2025, for an analyst call held on April 24, 2025 at 5:00 p.m. IST. FY 2025 consolidated revenue was ₹5,554 Cr, up 10%; EBITDA was ₹1,115 Cr with a 20.1% margin (up 4.2... NSE copy | +1203.1 % | +31.4 % | +6.1 % |
| 29 Jan 2025 | Laurus Labs filed the transcript of its Q3 FY25 earnings conference call, hosted on January 24, 2025. Management reported Q3 revenue of INR1,415 crores, up 18% year-on-year, and 9-month total income from operations of about INR3,834 crores, up 6%. Q3 EBITDA was INR285 crores at a 20.1% margin; Q3 profit after tax... NSE copy | +1203.1 % | +31.4 % | +6.1 % |
| 24 Jan 2025 | Laurus Labs filed its investor/analyst presentation on the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2024 (call held January 24, 2025, 5.00 PM IST). Management reported revenues of ₹ 3,834 Cr in 9M FY25, a 6% growth, and EBITDA of ₹ 638 Cr at a 16.6%... NSE copy | +1203.1 % | +31.4 % | +6.1 % |
Filings tagged as guidance, newest first (13 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 29 Oct 2026 | Management change | Board of Laurus Labs approved unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, with Limited Review Reports from Deloitte Haskins & Sells LLP. Consolidated revenue from operations for the quarter ended September 30, 2026 was Rs 2,206.37 crore, against Rs 2,026.31... NSE copy |
| 03 Jul 2026 | Credit rating | Laurus Labs Limited received the final credit rating letter from CARE Ratings Ltd. on July 03, 2026. Long-term bank facilities rated CARE AA; Stable, reaffirmed. Long-term/short-term bank facilities rated CARE AA; Stable / CARE A1+, reaffirmed. Short-term bank facilities rated CARE A1+, reaffirmed. The agency's... NSE copy |
| 28 Apr 2026 | Legal or regulatory | Laurus Labs responded to NSE clarification (dated January 12, 2026) on deficiencies in its October 23, 2025 financial results filing. The company attributed the lapses to a NEAPS portal technical glitch: the PDF was not converted to machine-readable format, and submission took a few minutes longer than the... NSE copy |
| 23 Jan 2026 | Legal or regulatory | Laurus Labs Limited's board on January 23, 2026 approved unaudited consolidated financial results for the quarter and nine months ended December 31, 2025, with a limited review report from Deloitte Haskins & Sells LLP. Consolidated total income for the quarter ended December 31, 2025 was Rs 1,784.05 crore, against... NSE copy |
| 21 Aug 2025 | Legal or regulatory | Board of Laurus Labs approved, subject to requisite approvals, a Composite Scheme of Arrangement under Sections 230-232 of the Companies Act, 2013, on August 21, 2025. The scheme demerges Unit-1 of wholly owned subsidiary Laurus Synthesis Private Limited into wholly owned subsidiary Sriam Labs Private Limited, and... NSE copy |
| 01 Jul 2025 | Credit rating | Laurus Labs Limited received the final credit rating letter from CARE Ratings Ltd. on July 01, 2025. Long-term bank facilities rated CARE AA; Stable, reaffirmed, with outlook revised from Negative to Stable. Short-term bank facilities rated CARE A1+, reaffirmed. CARE attributed the long-term outlook revision to... NSE copy |
| 15 May 2025 | Legal or regulatory | Outcome of the Board Meeting held on May 15, 2025, which ran from 2.00 p.m. to 2.30 p.m. The Board approved the notice convening the 20th Annual General Meeting on Thursday, June 26, 2025, through video conferencing / other audio visual means. June 19, 2025 is fixed as the cut-off date for e-voting in connection... NSE copy |
| 24 Apr 2025 | Legal or regulatory | Laurus Labs filed an investor/analyst presentation on its standalone and consolidated financial results for the quarter and year ended March 31, 2025, for an analyst call held on April 24, 2025 at 5:00 p.m. IST. FY 2025 consolidated revenue was ₹5,554 Cr, up 10%; EBITDA was ₹1,115 Cr with a 20.1% margin (up 4.2... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (8 in all). A list of what was filed, not a judgement of the company.